With an optimized set of reaction conditions, we next
investigated the scope and limitation of the tandem reac-
tion (Table 2). The reaction of secondary anilide 1b
afforded 2b exclusively in 31% yield, whose cyclization
to 3b seemed to be prohibited presumably due to confor-
mational reasons14 (entry 1). However, the tandem reac-
tion of cyanoacetanilides 1c,d substituted at amide
nitrogen with ethyl and benzyl groups took place smoothly
to afford the desired quinoxalinone-N-oxides 3c,d in 70%
and 98% yields, respectively (entries 2 and 3). Notably, the
N-oxides 3e,f were obtained in high yields (entries 4, 5)
since the halogenated products could in principle be
further functionalized by way of transition-metal-
catalyzed coupling reactions. Importantly, the tandem reac-
tions successfully proceeded with arenes bearing strong
electron-withdrawing substituents 1gÀj (entries 6À9). The
prolonged reaction time and decreased chemical yield
(entry 9) support the mechanism proposed above via
intramolecular electrophilic substitution. The following
results indicate that the cyclization step is sensitive to the
steric hindrance: (1) the cyclization of meta-substituted
cyanoacetanilide 1l,m occurred almost exclusively para
to the methyl and bromo group to afford 6-substituted
qunoxalinone-N-oxide 3l,m in 75% and 50% yields, re-
spectively (entries 11 and 12); and (2) ortho-substituted
cyanoacetanilide 1n was ineffective in the tandem reaction
(entry 13). It should be worth noting that the isolation of all
products 3cÀl could be readily accomplished by precipita-
tion and filtration.15
Table 2. Scope and Limitation of Tandem Nitrosation/Aerobic
Oxidative Cyclization of Cyanoacetanilides 1bÀna
(9) Although the aerobic oxidative cyclization of aci-nitroso species 2
has not been reported to our knowledge, a few cyclization reactions of
the related R-arylimino oximes have been reported; see: (a) Maroulis,
A. J.; Domzaridou, K. C.; Hadjiantoniou-Maroulis, C. P. Synthesis
1998, 1769. (b) Xekoukoulotakis, N. P.; Hadjiantoniou-Maroulis, C. P.;
Maroulis, A. J. Tetrahedron Lett. 2000, 41, 10299. (c) Aggarwal, R.;
Sumran, G.; Saini, A.; Singh, S. P. Tetrahedron Lett. 2006, 47, 4969.
(10) No cyclization of 2a was observed in the absence of NaNO2 or
H2SO4.
(11) For a gaseous NO2-mediated oxidative cyclization, see: (a)
ꢀ
Pasinszki, T.; Havasi, B.; Hajgato, B.; Westwood, N. P. C. J. Phys.
a All reactions were carried out with 1.0 mmol of 1 under air (open
Chem. A 2009, 113, 170. For selected recent examples for aerobic alcohol
oxidation utilizing NO2, see: (b) Liu, R.; Liang, X.; Dong, C.; Hu, X.
J. Am. Chem. Soc. 2004, 126, 4112. (c) Uyanik, M; Fukatsu, R.; Ishihara, K.
Chem.;Asian J. 2010, 5, 456. (d) Shibuya, M.; Osada, Y.; Sasano, Y.;
Tomizawa, M.; Iwabuchi, Y. J. Am. Chem. Soc. 2011, 133, 6497.
(12) Wang, K.; Fu, X.; Liu, J.; Liang, Y.; Dong, D. Org. Lett. 2009,
11, 1015.
(13) In the strongly acidic reaction media, an alternative mechanism
via an electrocyclic reaction of the dicationic intermediate C cannot be
ruled out.
flask). b Isolated yields.
Quinoxalinone derivatives, including 3,4-dihydroqui-
noxalinone, show important biological and pharmacological
properties and are widely used in material sciences.16,17
Therefore a number of synthetic methods have been reported
to date.18,19 We hypothesized that quinoxalinone-N-oxides20
could be used as intermediates for their preparation.21 In
particular, the CN group at the C2 position of 3 could be
(18) For selected recent examples for quinoxalinones, see: (a) Bi,
F. C.; Aspnes, G. E.; Guzman-Perez, A.; Walker, D. P. Tetrahedron
Lett. 2008, 49, 1832. (b) Chen, D.; Wang, Z.-J.; Bao, W. J. Org. Chem.
2010, 75, 5768.
(19) For selected recent examples for 3,4-dihydroquinoxalinones,
see: (a) Luo, X.; Chenard, E.; Martens, P.; Cheng, Y.-X.; Tomaszewski,
M. J. Org. Lett. 2010, 12, 3574. (b) Rueping, M.; Tato, F.; Schoepke,
F. R. Chem.;Eur. J. 2010, 16, 2688. (c) Chen, D.; Bao, W. Adv. Synth.
Catal. 2010, 352, 955. (d) Xue, Z.-Y.; Jiang, Y.; Peng, X.-Z.; Yuan, W.-C.;
Zhang, X.-M. Adv. Synth. Catal. 2010, 352, 2132. (e) Tanimori, S.;
Kashiwagi, H.; Nishimura, T.; Kirihata, M. Adv. Synth. Catal. 2010,
352, 2531.
(14) Itai, A.; Toriumi, Y.; Tomioka, N.; Kagechika, H.; Azumaya, I.;
Shudo, K. Tetrahedron Lett. 1989, 30, 6177 and references cited therein.
(15) For experimental details, see the Supporting Information.
(16) For recent examples of quinoxalinone derivatives, see: (a) Saoudi,
N.; Bellaouchou, A.; Guenbour, A.; Bachir, A. B.; Essassi, E.; Achouri,
M. E. Bull. Mater. Sci. 2010, 33, 313. (b) Galal, S. A.; Abdelsamie, A. S.;
Tokuda, H.; Suzuki, N.; Lida, A.; ElHefnawi, M. M.; Ramadan, R. A.;
Atta, M. H. E.; El Diwani, H. I. Eur. J. Med. Chem. 2011, 46, 327.
(17) For recent reviews on quinoxalinone scaffolds, see: (a) Li, X.;
Yang, K.; Li, W.; Xu, W. Drugs Future 2006, 31, 979. (b) Carta, A.; Piras,
S.; Loriga, G.; Paglietti, G. Mini-Rev. Med. Chem. 2006, 6, 1179.
6282
Org. Lett., Vol. 13, No. 23, 2011